Who
Robert P. Ragusa
Director
Company insider
Files Form 4 as: Director, Alamar Biosciences; Chief Executive Officer, Grail; Director, Twist Bioscience; SVP, Global Quality & Ops, Illumina; EVP Engineering & Global, Accuray.
In numbers
- Trades disclosed
- 102
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $34.0M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 28 Mar 2013
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | ALMR Alamar BiosciencesLife-science tools | SEC FORM 4 Code A | —5,686 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | ALMR Alamar Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —25,599 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | ALMR Alamar Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code A | —25,599 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | ALMR Alamar BiosciencesLife-science tools | SEC FORM 4 Code A | —5,686 at $0.00 | filing |
| 8 Apr 2026filed 9 Apr 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $6.2M123,502 at $49.92 | filing |
| 8 Apr 2026filed 9 Apr 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $6.2M123,502 at $49.92 | filing |
| 9 Mar 2026filed 9 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $345K7,203 at $47.93 | filing |
| 9 Mar 2026filed 9 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $12K258 at $46.73 | filing |
| 9 Mar 2026filed 9 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $345K7,203 at $47.93 | filing |
| 9 Mar 2026filed 9 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $12K258 at $46.73 | filing |
| 5 Mar 2026filed 9 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $52K980 at $53.01 | filing |
| 5 Mar 2026filed 9 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $52K980 at $53.01 | filing |
| 2 Mar 2026filed 3 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $1.8M35,787 at $50.09 | filing |
| 2 Mar 2026filed 3 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $89K1,717 at $51.84 | filing |
| 2 Mar 2026filed 3 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $1.8M35,787 at $50.09 | filing |
| 2 Mar 2026filed 3 Mar 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $89K1,717 at $51.84 | filing |
| 5 Feb 2026filed 9 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code A | —5,095 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | TWST Twist BioscienceGenomics & Gene Editing | SEC FORM 4 Code A | —5,095 at $0.00 | filing |
| 3 Dec 2025filed 5 Dec 2025 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $1.4M14,807 at $94.43 | filing |
| 3 Dec 2025filed 5 Dec 2025 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $1.5M15,356 at $95.28 | filing |
News
GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 20,000 Shares of StockGRAL · dailypolitical.com · 17 Oct 2026Jim Cramer Breaks Down the Stakes in Detail as GRAIL (GRAL) Awaits Its Next Big DecisionGRAL · insidermonkey.com · 10 Oct 2026
0 headlines in the last 90 days name Robert P. Ragusa; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.